BeOne Medicines (BEIGF) Free Cash Flow (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Free Cash Flow data on file, last reported at $158.1 million in Q1 2026.

• Free Cash Flow for Q1 2026 came in at $158.1 million, up 1092.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 368.26% YoY), and the FY2025 annual result was $941.7 million, up 546.44% from the prior year.
• Free Cash Flow slipped to $158.1 million in Q1 2026 per BEIGF's latest filing, from $283.6 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $408.4 million in Q3 2025 and troughed at -$675.9 million in Q4 2023.
• A 5-year average of -$148.6 million and a median of -$205.5 million in 2024 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2026: Free Cash Flow slumped 399.07% in 2022, then jumped 1092.51% in 2026.
• A 5-year view of Free Cash Flow shows it stood at -$439.5 million in 2022, then plunged by 53.78% to -$675.9 million in 2023, then soared by 159.92% to $405.0 million in 2024, then declined by 29.99% to $283.6 million in 2025, then slumped by 44.25% to $158.1 million in 2026.
• Business Quant data shows BEIGF's Free Cash Flow at $158.1 million in Q1 2026, $283.6 million in Q4 2025, and $408.4 million in Q3 2025.